# SLC35G2

## Overview
SLC35G2 is a gene that encodes the protein solute carrier family 35 member G2, which is part of the solute carrier family involved in the transport of nucleotide sugars. This protein is categorized as a putative vesicular transporter and is implicated in glycosylation processes within cells. It is predominantly localized in the Golgi apparatus, endosomes, and lysosomes, suggesting a role in the transport and modification of glycosylated proteins and lipids, which are essential for cellular metabolism and homeostasis (Meng2023SLC35G2). In the nervous system, SLC35G2 is associated with synaptic vesicles, indicating a potential involvement in neurotransmission (Qian2020Localization). Clinically, SLC35G2 has been identified as a prognostic biomarker in various cancers, including hepatocellular carcinoma and colorectal cancer, where its expression levels correlate with disease progression and immune response (Xiao2024Disulfidptosisrelated; Meng2023SLC35G2).

## Function
SLC35G2 is a member of the solute carrier family involved in the transport of nucleotide sugars, which are crucial for glycosylation processes within cells. This protein is identified as a putative vesicular transporter, potentially localizing to synaptic vesicles in neurons. It shows a high co-localization ratio with synaptophysin, a synaptic vesicle protein, suggesting its role in vesicular transport processes in the nervous system (Qian2020Localization). Proteomics analysis has identified SLC35G2 among synaptic vesicle-associated proteins, with an abundance similar to known vesicular neurotransmitter transporters, indicating its potential involvement in neurotransmission (Qian2020Localization).

In terms of subcellular localization, SLC35G2 is identified in the Golgi apparatus, endosomes, and lysosomes, suggesting its involvement in nucleoside-sugar transport across these organelles (Meng2023SLC35G2). This localization pattern implies a role in the modification and transport of glycosylated proteins and lipids, impacting cellular metabolism and homeostasis. While specific biochemical functions in healthy human cells are not fully detailed, the presence of SLC35G2 in these cellular compartments highlights its potential role in maintaining cellular processes related to glycosylation and vesicular transport (Meng2023SLC35G2).

## Clinical Significance
SLC35G2 has been identified as a prognostic biomarker in hepatocellular carcinoma (HCC), with its abnormal expression linked to poor overall survival and disease-specific survival. It is significantly upregulated in HCC tissues compared to normal tissues, making it an independent prognostic factor. High expression of SLC35G2 is associated with immunosuppressive and pro-tumor signaling pathways, suggesting its role in tumor progression. The gene's expression is positively correlated with immune cells such as T helper, Th2, and macrophages, and negatively correlated with eosinophils and Th17 cells. It is also associated with immune checkpoint markers like CTLA4 and PD-L1, indicating potential implications for immunotherapy in HCC (Meng2023SLC35G2).

In colorectal cancer (CRC), SLC35G2 is part of a disulfidptosis-related prognostic signature that correlates with immune system escape and affects the response to immunotherapy. High expression levels are considered a risk factor for poor prognosis in CRC patients (Xiao2024Disulfidptosisrelated).

SLC35G2 has also been implicated in glioma, where its expression or methylation alterations might have clinical significance, although direct evidence is limited (Zhang2020Distinguishing). Additionally, SLC35G2 has been identified as a novel candidate gene potentially associated with epilepsy, though its clinical significance in this context requires further investigation (Jiang2021Application).


## References


1. (Meng2023SLC35G2) SLC35G2 as a Prognostic Biomarker in Hepatocellular carcinoma and Its Correlation with Immunity. This article has 0 citations.

2. (Qian2020Localization) Localization, proteomics, and metabolite profiling reveal a putative vesicular transporter for UDP-glucose. This article has 0 citations.

[3. (Zhang2020Distinguishing) Yu-Hang Zhang, Zhandong Li, Tao Zeng, Xiaoyong Pan, Lei Chen, Dejing Liu, Hao Li, Tao Huang, and Yu-Dong Cai. Distinguishing glioblastoma subtypes by methylation signatures. Frontiers in Genetics, November 2020. URL: http://dx.doi.org/10.3389/fgene.2020.604336, doi:10.3389/fgene.2020.604336. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2020.604336)

[4. (Jiang2021Application) Tiejia Jiang, Jia Gao, Lihua Jiang, Lu Xu, Congying Zhao, Xiaojun Su, Yaping Shen, Weiyue Gu, Xiaohong Kong, Ying Yang, and Feng Gao. Application of trio-whole exome sequencing in genetic diagnosis and therapy in chinese children with epilepsy. Frontiers in Molecular Neuroscience, August 2021. URL: http://dx.doi.org/10.3389/fnmol.2021.699574, doi:10.3389/fnmol.2021.699574. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnmol.2021.699574)

[5. (Xiao2024Disulfidptosisrelated) Yu Xiao, Hancui Lin, Jinluan Li, and Junxin Wu. Disulfidptosis-related prognostic signature correlates with immunotherapy response in colorectal cancer. Scientific Reports, January 2024. URL: http://dx.doi.org/10.1038/s41598-023-49954-w, doi:10.1038/s41598-023-49954-w. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-023-49954-w)